Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience

Sarah A Holstein, Philip L. McCarthy

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell malignancy, have dramatically improved. The development of the immunomodulatory drugs (IMiDs), which include thalidomide, lenalidomide, and pomalidomide, has contributed significantly to these improved outcomes. While thalidomide is now less commonly prescribed, lenalidomide is widely used in the treatment of newly diagnosed transplant-eligible and transplant-ineligible patients, in the maintenance setting post-transplant and in the relapsed/refractory setting, while pomalidomide is currently utilized in the relapsed/refractory setting. The IMiDs have been reported to have a multitude of activities, including anti-angiogenic, cytotoxic, and immunomodulatory. However, the more recent discoveries that the IMiDs bind to cereblon and thus regulate the ubiquitination of key transcription factors including IKZF1 and IKZF3 have provided greater insight into their mechanism of action. Here, the clinical efficacy of these agents in myeloma is reviewed and the structure-function relationship, the molecular mechanisms of action, and the association of IMiDs with second primary malignancies and thrombosis are discussed.

Original languageEnglish (US)
Pages (from-to)505-520
Number of pages16
JournalDrugs
Volume77
Issue number5
DOIs
StatePublished - Apr 1 2017

Fingerprint

Multiple Myeloma
Thalidomide
Transplants
Pharmaceutical Preparations
Second Primary Neoplasms
Ubiquitination
Plasma Cells
Thrombosis
Transcription Factors
Maintenance
Neoplasms
lenalidomide
pomalidomide
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Immunomodulatory Drugs in Multiple Myeloma : Mechanisms of Action and Clinical Experience. / Holstein, Sarah A; McCarthy, Philip L.

In: Drugs, Vol. 77, No. 5, 01.04.2017, p. 505-520.

Research output: Contribution to journalReview article

@article{366a167554b64f60b48b546d1100896b,
title = "Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience",
abstract = "Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell malignancy, have dramatically improved. The development of the immunomodulatory drugs (IMiDs), which include thalidomide, lenalidomide, and pomalidomide, has contributed significantly to these improved outcomes. While thalidomide is now less commonly prescribed, lenalidomide is widely used in the treatment of newly diagnosed transplant-eligible and transplant-ineligible patients, in the maintenance setting post-transplant and in the relapsed/refractory setting, while pomalidomide is currently utilized in the relapsed/refractory setting. The IMiDs have been reported to have a multitude of activities, including anti-angiogenic, cytotoxic, and immunomodulatory. However, the more recent discoveries that the IMiDs bind to cereblon and thus regulate the ubiquitination of key transcription factors including IKZF1 and IKZF3 have provided greater insight into their mechanism of action. Here, the clinical efficacy of these agents in myeloma is reviewed and the structure-function relationship, the molecular mechanisms of action, and the association of IMiDs with second primary malignancies and thrombosis are discussed.",
author = "Holstein, {Sarah A} and McCarthy, {Philip L.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s40265-017-0689-1",
language = "English (US)",
volume = "77",
pages = "505--520",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Immunomodulatory Drugs in Multiple Myeloma

T2 - Mechanisms of Action and Clinical Experience

AU - Holstein, Sarah A

AU - McCarthy, Philip L.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell malignancy, have dramatically improved. The development of the immunomodulatory drugs (IMiDs), which include thalidomide, lenalidomide, and pomalidomide, has contributed significantly to these improved outcomes. While thalidomide is now less commonly prescribed, lenalidomide is widely used in the treatment of newly diagnosed transplant-eligible and transplant-ineligible patients, in the maintenance setting post-transplant and in the relapsed/refractory setting, while pomalidomide is currently utilized in the relapsed/refractory setting. The IMiDs have been reported to have a multitude of activities, including anti-angiogenic, cytotoxic, and immunomodulatory. However, the more recent discoveries that the IMiDs bind to cereblon and thus regulate the ubiquitination of key transcription factors including IKZF1 and IKZF3 have provided greater insight into their mechanism of action. Here, the clinical efficacy of these agents in myeloma is reviewed and the structure-function relationship, the molecular mechanisms of action, and the association of IMiDs with second primary malignancies and thrombosis are discussed.

AB - Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell malignancy, have dramatically improved. The development of the immunomodulatory drugs (IMiDs), which include thalidomide, lenalidomide, and pomalidomide, has contributed significantly to these improved outcomes. While thalidomide is now less commonly prescribed, lenalidomide is widely used in the treatment of newly diagnosed transplant-eligible and transplant-ineligible patients, in the maintenance setting post-transplant and in the relapsed/refractory setting, while pomalidomide is currently utilized in the relapsed/refractory setting. The IMiDs have been reported to have a multitude of activities, including anti-angiogenic, cytotoxic, and immunomodulatory. However, the more recent discoveries that the IMiDs bind to cereblon and thus regulate the ubiquitination of key transcription factors including IKZF1 and IKZF3 have provided greater insight into their mechanism of action. Here, the clinical efficacy of these agents in myeloma is reviewed and the structure-function relationship, the molecular mechanisms of action, and the association of IMiDs with second primary malignancies and thrombosis are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85012886811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012886811&partnerID=8YFLogxK

U2 - 10.1007/s40265-017-0689-1

DO - 10.1007/s40265-017-0689-1

M3 - Review article

C2 - 28205024

AN - SCOPUS:85012886811

VL - 77

SP - 505

EP - 520

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 5

ER -